ReviewHeart failure reviews2012
Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes.
Review in Heart failure reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 37 citations in OpenAlex.
- Current Controversies on Adequate Circulating Vitamin D Levels in CKD.International journal of molecular sciences · 2025Review
- Vitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease?International urology and nephrology · 2025Review
- Non-classical Vitamin D Actions for Renal Protection.Frontiers in medicine · 2021Review
- Serum PTH levels in dialysis: better safe than sorry.Therapeutic advances in endocrinology and metabolism · 2020Article
- Vitamin D metabolites and fibroblast growth factor-23 in patients with left ventricular assist device implants: association with stroke and mortality risk.European journal of nutrition · 2016Article
- Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2015Review
- Effect of VDRA on survival in incident hemodialysis patients: results of the FARO-2 observational study.BMC nephrology · 2015Observational
- The beneficial impact of vitamin D treatment in CKD patients: what's next?Clinical kidney journal · 2015Article
- Management of cardiorenal metabolic syndrome in diabetes mellitus: a phytotherapeutic perspective.Journal of diabetes research · 2014Review
- The puzzle of kidney dysfunction in heart failure: an introduction.Heart failure reviews · 2012Article
- Cardio-renal cachexia syndromes (CRCS): pathophysiological foundations of a vicious pathological circle.Journal of cachexia, sarcopenia and muscle · 2011Article
- Reversible Cardio-Renal-Cerebral Syndrome in a Dog: A Case Report.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, it has become increasingly clear that the cardiovascular and renal systems are interdependent. Primary disorders of either system have been shown to disturb the other system. As a result, a class of cardiorenal syndromes (CRS) has been identified wherein a vicious cycle is established as an acute/chronic dysfunction of either the kidney or the heart exacerbates the loss of function in the other organ. Progressive loss of kidney function observed in patients with CRS (mostly types 2 and 4) leads to reduced production of calcitriol (active vitamin D) and an imbalance in calcium and phosphorus levels, which are correlated with increased rates of cardiovascular events and mortality. In addition, hypocalcemia can lead to prolonged and excessive secretion of parathyroid hormone (PTH), eventually leading to development of secondary hyperparathyroidism. Therefore, based on this important mechanism of organ damage, one of the major goals of therapy for patients with CRS is to restore regulatory control of PTH. Although administration of calcitriol increases serum calcium levels and reduces PTH levels, it is also associated with elevated serum levels of calcium-phosphorus product. Therefore, compounds that selectively activate vitamin D receptors, potentially reducing calcium × phosphate toxicity, are likely to enhance cardiorenal protection and provide significant clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.